Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study.

From this time point onwards the percentage of patients with normalized SAA levels was numerically greater for all canakinumab groups compared with triamcinolone acetonide, but the difference did not reach statistical significance for most doses or time points (Table 1 ).

also in 111,027 other papers